report cover1

Lungs Disease Therapeutics Market "(By Type of Disease: Asthma, COPD, Cystic Fibrosis, Pulmonary Arterial Hypertension (PAH), Idiopathic Pulmonary Fibrosis (IPF), Others); (By Type of Therapy: Bronchodilators, Corticosteroids, Monoclonal Antibodies, Combination Therapy, Others); (By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)”- Industry Analysis, Size, Share, Growth, Trends, And Forecast, 2022-2030

A prominent research firm, Cognizance Market Research added a cutting-edge industry report on “Global Lungs Disease Therapeutics Market”. The report studies the current as well as past growth trends and opportunities for the market to gain valuable insights during the forecast period from 2022 to 2030.

Lungs Disease Therapeutics Market Analysis:

According to cognizance market research the Lungs Disease Therapeutics Market is expected to register a CAGR of 3.9% from 2022 to 2030.

lungs disease therapeutics market

What is Lungs Disease Therapeutics Market?

The term “lung disease therapeutics” refers to the variety of medical procedures and pharmacological items used to control and treat pulmonary diseases and disorders. These ailments include lung cancer, asthma, pulmonary fibrosis, cystic fibrosis, chronic obstructive pulmonary disease (COPD), and others. Depending on the individual problem and the severity of the sickness, many treatment options are available for these conditions.

Inhalers and nebulizers are frequently used to administer medicines directly to the lungs, providing asthma sufferers and those with other respiratory disorders with quick and efficient relief. Additionally, the use of oral drugs such as bronchodilators, corticosteroids, and antibiotics is utilised to treat symptoms and enhance the functioning of the lungs.

The pharmaceutical industry’s lung disease therapeutics market specialises in creating, manufacturing and dispensing pharmaceuticals and medical equipment for the diagnosis and treatment of respiratory illnesses. The illnesses included are lung cancer, pulmonary fibrosis, asthma and COPD. The market offers a range of goods, such as oral drugs, biologists, nebulisers, oxygen treatment equipment, and inhalers.

The rising frequency of respiratory disorders, particularly in older persons, is the main factor driving the market for treatment for lung diseases. The burden of respiratory disorders is increasing globally due to a number of causes, including an ageing population, raising pollution levels, and lifestyle choices including smoking and poor diets. Pharmaceutical companies are spending a lot of money on research and development to find novel and efficient medicines for this illness.

Innovations in medical technology and drug development which have resulted in the launch of novel and more effective therapies for respiratory disorders are also driving the market. However, some of the biggest difficulties faced by competitors in the lung diseases therapeutics market are regulatory obstacles, high research and the drawn-out approval procedure for new pharmaceutical and medical devices.

Lungs Disease Therapeutics Market Outlook:

In the upcoming years, the market for therapies for lung diseases is anticipated to expand at a steady rate thanks to a number of factors. The rising incidence of respiratory disorders, particularly in ageing populations, is one of the main contributors. The prevalence of respiratory disorders like COPD and asthma are rising along with air pollution levels and sedentary lifestyles.

The market for therapies for lung diseases is expanding as a result of developments in medical technology and drug discovery. The demand for these goods is been fuelled by the development of novel therapies and equipment, such as portable oxygen concentrators and biologics, which are improving outcomes for patients with respiratory disorders.

The market does face certain difficulties, though. Smaller firms may find it challenging to compete in the market due to regulatory obstacles and the high cost of drug development. Additionally, the COVID-19 pandemic has had a considerable influence on the market for treatments for lung diseases, causing delays in clinical studies and interruptions to supply chains.

The development of biologics, combination therapy, personalised medicines, digital health technologies, and growth potential in new regions are among the major trends and opportunities in the therapeutic market for lung diseases. These advancements aim to promote access to healthcare to people with respiratory disorders, individualise treatment techniques, and improve treatment efficacy. As new tools and therapies are created to address the rising burden of respiratory disorders, the market is anticipated to expand.

Segment Analysis:

The lungs disease therapeutics market can be segmented by type of disease, type of therapy, and distribution channel.

By type of disease:

Asthma: A persistent respiratory condition called asthma results in inflammation and airway narrowing like wheezing, coughing and shortness of breath.

COPD (Chronic Obstructive Pulmonary Disease): Chronic bronchitis and emphysema are two of the lung disorders in the COPD category that progressively block airways and make breathing difficult.

Cystic Fibrosis: Mucus build up in the lungs and other organs as a result of the hereditary condition cystic fibrosis, which affects the digestive and respiratory systems.

Pulmonary Arterial Hypertension (PAH): A uncommon and progressive kind of high pressure that affects the arteries in the lungs is referred to as pulmonary arterial hypertension.

Idiopathic Pulmonary Fibrosis (IPF): It is a form of interstitial lung disease that results in lung tissue stiffening and scarring, making it difficult to breathe and impairing lung function.

Others: Lung cancer, bronchiectasis, and pulmonary embolism are examples of respiratory illnesses.

COPD is the leading sector because of its high incidence and an enormous burden on healthcare systems throughout the world. COPD is expected to be the third biggest cause of mortality globally by 2030, according to the World Health Organization.

By treatment type:

Bronchodilators are drugs that relax and enlarge the airways, making breathing easier. Bronchodilators, both short and long-acting, are included.

Corticosteroids are anti-inflammatory drugs that assist to relieve the symptoms of respiratory disorders by reducing swelling and inflammation in the airways.

Monoclonal antibodies are biological medications that target molecules in the immune system to treat respiratory disorders such as severe asthma and COPD.

Combination Therapy: the administration of two or more medications with distinct mechanisms of action in order to enhance symptom management and outcomes in patients with respiratory disorders.

Other options include oxygen therapy, pulmonary rehabilitation, and lung transplantation.

Bronchodilators are the market leader due to their extensive usage in the treatment of respiratory illnesses such as asthma and COPD.

By channel of distribution:

Hospital Pharmacies: These are pharmacies that are housed within hospitals and provide acute treatment and management of respiratory disorders.

Retail Pharmacies: typical brick-and-mortar pharmacies that provide customers with a convenient way to fill prescriptions and obtain over-the-counter respiratory treatments.

Online pharmacies are a rising market sector that provides patients with simple access to respiratory illness treatments as well as home delivery services.

Hospital pharmacies are the market leader due to their involvement in providing acute treatment and managing respiratory disorders.

It is important to note that these figures may differ based on the source and methodology utilised to gather and evaluate the data. However, these divisions can give useful insights into the dynamics of the lung disease treatments market and assist players in making educated decisions regarding product development, marketing, and distribution strategies.

Geographical Analysis:

Based on geography the Lungs Disease Therapeutics Market has been segmented into five main regions namely, North America, Asia Pacific, Europe, Latin America, and Middle East & Africa.

Because of the high frequency of respiratory disorders, well-established healthcare infrastructure, and high healthcare spending, North America is the largest market for lung disease therapies. Major companies in this region, such as GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim, also contribute to market growth.

Due to the high incidence of respiratory disorders, good reimbursement policies, and rising use of sophisticated medicines, Europe is the second biggest market for lungs disease therapeutics. The existence of significant companies such as Novartis, Teva Pharmaceutical Industries Ltd., and Chiesi Farmaceutici S.p.A. also drives the industry.

Because of the increasing frequency of respiratory illnesses, rising healthcare spending, and expanding demand for innovative medicines, the Asia-Pacific region is the fastest-growing market for lung disease therapeutics. The existence of large firms such as GlaxoSmithKline, Novartis, and AstraZeneca significantly drives the industry.

Other regions, such as Latin America, the Middle East, and Africa, are likely to have considerable growth as a result of increased respiratory illness prevalence and healthcare costs.

geographical analysis


The report offers the revenue of the Lungs Disease Therapeutics Market for the period 2020-2030, considering 2020 & 2021 as a historical years, 2022 as the base year and 2023 to 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the Lungs Disease Therapeutics Market for the forecast period. The Lungs Disease Therapeutics Market report provides insights and in-depth analysis into developments impacting enterprises and businesses on a regional and global level. The report covers the Lungs Disease Therapeutics Market performance in terms of revenue contribution from several segments and comprises a detailed analysis of key drivers, trends, restraints, and opportunities prompting revenue growth of the Lungs Disease Therapeutics Market.

The report has been prepared after wide-ranging secondary and primary research. Secondary research included internet sources, numerical data from government organizations, trade associations, and websites. Analysts have also employed an amalgamation of bottom-up and top-down approaches to study numerous phenomena in the Lungs Disease Therapeutics Market. Secondary research involved a detailed analysis of significant players’ product portfolio. Literature review, press releases, annual reports, white paper, and relevant documents have been also studied to understand the Lungs Disease Therapeutics Market. Primary research involved a great extent of research efforts, wherein experts carried out interviews telephonic as well as questioner-based with industry experts and opinion-makers.

The report includes an executive summary, along with a growth pattern of different segmented included in the scope of the study. The Y-o-Y analysis with elaborate market insights has been provided in the report to comprehend the Y-o-Y trends in the Lungs Disease Therapeutics Market. Additionally, the report focuses on altering competitive dynamics in the global market. These indices serve as valued tools for present market players as well as for companies interested in participating in the Lungs Disease Therapeutics Market. The subsequent section of the Lungs Disease Therapeutics Market report highlights the USPs, which include key industry events (Type launch, research partnership, acquisition, etc.), technology advancements, pipeline analysis, prevalence data, and regulatory scenario.

Lungs Disease Therapeutics Market Competitive Landscape:

The lungs disease therapeutics market is highly competitive, with a large number of companies operating in the space. Some of the leading companies in the market include:

  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Novartis International AG
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Hoffmann-La Roche AG
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • AbbVie, Inc.
  • Vertex Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Cipla, Inc.
  • Reddy’s Laboratories Ltd.
  • Lupin Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Chiesi Farmaceutici S.p.A.
  • Circassia Pharmaceuticals plc
  • Kyorin Pharmaceutical Co., Ltd.
  • Verona Pharma plc
  • Thera Vance Biopharma, Inc.
  • Innoviva, Inc.
  • Orion Corporation
  • Insmed, Inc.

AstraZeneca plc and Amgen, Inc. have announced a cooperation to develop and market an asthma and chronic obstructive pulmonary disease therapy (COPD). Tezepelumab, a possible first-in-class drug that addresses the underlying causes of severe respiratory disorders, will be developed and commercialised collaboratively by the two firms.

In another development, Boehringer Ingelheim International GmbH announced the release of Spiolto Respimat, a novel COPD inhaler device. To promote symptom alleviation and lung function, the gadget contains two active substances, tiotropium and olodaterol.

The report explores the competitive scenario of the Lungs Disease Therapeutics Market. Major players working in the Lungs Disease Therapeutics Market have been named and profiled for unique commercial attributes. Company overview (company description, Type portfolio, geographic presence, employee strength, Key management, etc.), financials, SWOT analysis, recent developments, and key strategies are some of the features of companies profiled in the Lungs Disease Therapeutics Market report.


Global Lungs Disease Therapeutics Market, By Type of Disease:

  • Asthma
  • COPD
  • Cystic Fibrosis
  • Pulmonary Arterial Hypertension (PAH)
  • Idiopathic Pulmonary Fibrosis (IPF)
  • Others

Global Lungs Disease Therapeutics Market, By Type of Therapy:

  • Bronchodilators
  • Corticosteroids
  • Monoclonal Antibodies
  • Combination Therapy
  • Others

Global Lungs Disease Therapeutics Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Lungs Disease Therapeutics Market, by Region:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia & New Zealand
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
Complete the form below and we'll get back to you shortly
Table of Content

Research Methodology: Aspects

Market research is a crucial tool for organizations aiming to navigate the dynamic landscape of customer preferences, business trends, and competitive landscapes. At Cognizance Market Research, acknowledging the importance of robust research methodologies is vital to delivering actionable insights to our clientele. The significance of such methodologies lies in their capability to offer clarity in complexity, guiding strategic management with realistic evidence rather than speculation. Our clientele seek insights that excel superficial observations, reaching deep into the details of consumer behaviours, market dynamics, and evolving opportunities. These insights serve as the basis upon which businesses craft tailored approaches, optimize product offerings, and gain a competitive edge in an ever-growing marketplace.

The frequency of information updates is a cornerstone of our commitment to providing timely, relevant, and accurate insights. Cognizance Market Research adheres to a rigorous schedule of data collection, analysis, and distribution to ensure that our reports reflect the most current market realities. This proactive approach enables our clients to stay ahead of the curve, capitalize on emerging trends, and mitigate risks associated with outdated information.

Our research process is characterized by meticulous attention to detail and methodological rigor. It begins with a comprehensive understanding of client objectives, industry dynamics, and research scope. Leveraging a combination of primary and secondary research methodologies, we gather data from diverse sources including surveys, interviews, industry reports, and proprietary databases. Rigorous data analysis techniques are then employed to derive meaningful insights, identify patterns, and uncover actionable recommendations. Throughout the process, we remain vigilant in upholding the highest standards of data integrity, ensuring that our findings are robust, reliable, and actionable.

Key phases involved in in our research process are mentioned below:


Understanding Clients’ Objectives:

Extensive Discussions and Consultations:

  • We initiate in-depth discussions and consultations with our clients to gain a comprehensive understanding of their objectives. This involves actively listening to their needs, concerns, and aspirations regarding the research project.
  • Through these interactions, we aim to uncover the underlying motivations driving their research requirements and the specific outcomes they hope to achieve.

Industry and Market Segment Analysis:

  • We invest time and effort in comprehensively understanding our clients’ industry and market segment. This involves conducting thorough research into market trends, competitive dynamics, regulatory frameworks, and emerging opportunities or threats.
  • By acquiring a deep understanding of the broader industry landscape, we can provide context-rich insights that resonate with our clients’ strategic objectives.

Target Audience Understanding:

  • We analyze our clients’ target audience demographics, behaviors, preferences, and needs to align our research efforts with their consumer-centric objectives. This entails segmenting the audience based on various criteria such as age, gender, income level, geographic location, and psychographic factors.
  • By understanding the nuances of the target audience, we can tailor our research methodologies to gather relevant data that illuminates consumer perceptions, attitudes, and purchase intent.


Identifying Challenges and Opportunities:

  • We proactively identify the challenges and opportunities facing our clients within their respective industries. This involves conducting SWOT (Strengths, Weaknesses, Opportunities, Threats) analyses and competitive benchmarking exercises.
  • By identifying potential obstacles and growth drivers, we can provide strategic recommendations that help our clients navigate complexities and capitalize on emerging opportunities effectively.

Grasping Specific Goals:

  • We delve into the intricacies of our clients’ objectives to gain clarity on the specific goals they aim to accomplish through the research. This entails understanding their desired outcomes, such as market expansion, product development, or competitive analysis.
  • By gaining a nuanced understanding of our clients’ goals, we can tailor our research approach to address their unique challenges and opportunities effectively.

Data Collection:


Primary Research Process:

  • Surveys: We design and administer surveys tailored to capture specific information relevant to our clients’ objectives. This may involve employing various survey methodologies, such as online, telephone, or face-to-face interviews, to reach target audiences effectively.
  • Interviews: We conduct structured or semi-structured interviews with key stakeholders, industry experts, or target consumers to gather in-depth insights and perspectives on relevant topics. These interviews allow us to probe deeper into specific issues and uncover valuable qualitative data.
  • Focus Groups: We organize focus group discussions with carefully selected participants to facilitate interactive discussions and gather collective opinions, attitudes, and preferences. This qualitative research method provides rich contextual insights into consumer behaviors and perceptions.
  • Observations: We conduct observational research by directly observing consumer behaviors, interactions, and experiences in real-world settings. This method enables us to gather objective data on consumer actions and reactions without relying on self-reported information.

Secondary Research Process:

  • Literature Review: We conduct comprehensive literature reviews to identify existing studies, academic articles, and industry reports relevant to the research topic. This helps us gain insights into previous research findings, theoretical frameworks, and best practices.
  • Industry Reports: We analyze industry reports published by reputable trade associations (whitepapers, research studies, etc.), and government agencies (U.S. Census Bureau, Bureau of Labor Statistics, and Securities and Exchange Commission etc.) to obtain macro-level insights into market trends, competitive landscapes, and industry dynamics.
  • Government Publications: We review government publications, such as economic reports, regulatory documents, and statistical databases, to gather relevant data on demographics, market size, consumer spending patterns, and regulatory frameworks.
  • Online Databases: We leverage online databases, such as industry portals, and academic repositories (PubMed Central (PMC), ScienceDirect, SSRN (Social Science Research Network), Directory of Open Access Journals (DOAJ), NCBI, etc.), to access a wide range of secondary data sources, including market statistics, financial data, and industry analyses.





Data Analysis:

The data analysis phase serves as a critical juncture where raw data is transformed into actionable insights that inform strategic decision-making. Through the utilization of analytical methods such as statistical analysis and qualitative techniques like thematic coding, we uncover patterns, correlations, and trends within the data. By ensuring the integrity and validity of our findings, we strive to provide clients with accurate and reliable insights that accurately reflect the realities of the market landscape.



Transformation of Raw Data:

  • Upon collecting the necessary data, we transition into the data analysis phase, where raw data is processed and transformed into actionable insights. This involves organizing, cleaning, and structuring the data to prepare it for analysis.

Utilization of Analytical Methods:

  • Depending on the research objectives, we employ a diverse range of analytical methods to extract meaningful insights from the data. These methods include statistical analysis, trend analysis, regression analysis, and qualitative coding.

Statistical Analysis:

  • Statistical tools are instrumental in uncovering patterns, correlations, and trends within the data. By applying statistical techniques such as descriptive statistics, hypothesis testing, and multivariate analysis, we can discern relationships and derive valuable insights.

Qualitative Analysis Techniques:

  • In addition to quantitative analysis, we leverage qualitative analysis techniques to gain deeper insights from qualitative data sources such as interviews or open-ended survey responses. One such technique is thematic coding, which involves systematically categorizing and interpreting themes or patterns within qualitative data.

Integrity and Validity Maintenance:

  • Throughout the analysis process, we maintain a steadfast commitment to upholding the integrity and validity of our findings. This entails rigorous adherence to established methodologies, transparency in data handling, and thorough validation of analytical outcomes.

Data Validation:

The final phase of our research methodology is data validation, which is essential for ensuring the reliability and credibility of our findings. Validation involves scrutinizing the collected data to identify any inconsistencies, errors, or biases that may have crept in during the research process. We employ various validation techniques, including cross-referencing data from multiple sources, conducting validity checks on survey instruments, and seeking feedback from independent experts or peer reviewers. Additionally, we leverage internal quality assurance protocols to verify the accuracy and integrity of our analysis. By subjecting our findings to rigorous validation procedures, we instill confidence in our clients that the insights they receive are robust, reliable, and trustworthy.


Importance of Data Validation:

  • Data validation is the final phase of the research methodology, crucial for ensuring the reliability and credibility of the findings. It involves a systematic process of reviewing and verifying the collected data to detect any inconsistencies, errors, or biases.

Scrutiny of Collected Data:

  • The validation process begins with a thorough scrutiny of the collected data to identify any discrepancies or anomalies. This entails comparing data points, checking for outliers, and verifying the accuracy of data entries against the original sources.

Validation Techniques:

  • Various validation techniques are employed to ensure the accuracy and integrity of the data. These include cross-referencing data from multiple sources to corroborate findings, conducting validity checks on survey instruments to assess the reliability of responses, and seeking feedback from independent experts or peer reviewers to validate the interpretation of results.

Internal Quality Assurance Protocols:

  • In addition to external validation measures, internal quality assurance protocols are implemented to further validate the accuracy of the analysis. This may involve conducting internal audits, peer reviews, or data validation checks to ensure that the research process adheres to established standards and guidelines.

Report Scope:



Market Size

US$ 79.7 Billion (2030)

Compound Annual Growth Rate (CAGR)


Base Year


Forecast Period


Forecast Units

Value (US$ Billion)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

Geographies Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Countries Covered

U.S., Canada, Germany, U.K., France, Spain, Italy, Rest of Europe, Japan, China, India, Australia & New Zealand, South Korea, Rest of Asia Pacific, Brazil, Mexico, Rest of Latin America, GCC, South Africa, Rest of Middle East & Africa

Key Companies Profiled

GlaxoSmithKline plc, AstraZeneca plc, Novartis International AG, Boehringer Ingelheim International GmbH, Merck & Co., Inc., Pfizer, Inc., Hoffmann-La Roche AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Mylan N.V., AbbVie, Inc., Vertex Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Cipla, Inc., Reddy’s Laboratories Ltd., Lupin Pharmaceuticals, Inc., Glenmark Pharmaceuticals Ltd., Chiesi Farmaceutici S.p.A., Circassia Pharmaceuticals plc, Kyorin Pharmaceutical Co., Ltd., Verona Pharma plc, Thera Vance Biopharma, Inc., Innoviva, Inc., Orion Corporation, Insmed, Inc.

Key Questions Answered in Lungs Disease Therapeutics Market Report

The global lungs disease therapeutics market is a segment of the pharmaceutical industry that specializes in the development, manufacturing, and distribution of pharmaceuticals and medical devices for the diagnosis and treatment of respiratory diseases. These diseases include lung cancer, pulmonary fibrosis, asthma, and chronic obstructive pulmonary disease (COPD). The market offers a range of products, such as oral drugs, biologics, nebulizers, oxygen treatment equipment, and inhalers.

The key drivers of growth in the global lungs disease therapeutics market include:

  • Rising incidence of respiratory disorders, particularly in ageing populations
  • Increasing air pollution levels and sedentary lifestyles
  • Growing demand for novel and effective therapies
  • Technological advancements in medical devices and drug development

The key challenges facing the global lungs disease therapeutics market include:

  • Regulatory obstacles
  • High cost of drug development
  • Drawn-out approval process for new pharmaceutical and medical devices

North America is currently the largest market for lungs disease therapeutics, due to the high frequency of respiratory disorders, well-established healthcare infrastructure, and high healthcare spending. However, the Asia-Pacific region is expected to grow at the fastest rate in the coming years, due to the increasing frequency of respiratory illnesses, rising healthcare spending, and expanding demand for innovative medicines.

The opportunities for market players in the global lungs disease therapeutics market include:

  • Developing new and innovative therapies for respiratory disorders
  • Expanding into emerging markets
  • Partnering with other companies to develop and commercialize new products
  • Investing in research and development to improve the efficacy and safety of existing therapies
Single User - $4,600.00

It allows one person, the buyer, to have the sole rights and access to the purchased report. Further distribution of the product is strictly prohibited.

It allows the purchased product to be shared among 1-7 employees of your organization within the same geographical location.

It allows the purchased product to be shared among all employees of your organization irrespective of their geographical location.

Need a Custom Report?

We can customize every report – free of charge – including purchasing stand-alone sections or country-level reports

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Business Development

small c popup.png
Complete the form below and we'll get back to you shortly
small c popup.png
Complete the form below and we'll get back to you shortly
small c popup.png
Complete the form below and we'll get back to you shortly
Ask an Expert